Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Esophageal Neoplasms 5Colonic Neoplasms 5Stomach Neoplasms 4Colorectal Neoplasms 4Adenocarcinoma Of Esophagus 4Rectal Neoplasms 3Pancreatic Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Liver Neoplasms 2Burkitt Lymphoma 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Teratoma 1Squamous Cell Carcinoma of Head and Neck 1Spinal Cord Neoplasms 1Sezary Syndrome 1Sarcoma 1Salivary Gland Neoplasms 1Rhabdoid Tumor 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Ovarian Germ Cell Cancer 1Osteosarcoma 1Optic Nerve Glioma 1

Interventions

Gemcitabine 61Cisplatin 39Oxaliplatin 31Capecitabine 29Fluorouracil 22Leucovorin 20Irinotecan 12pembrolizumab 11130-nm albumin-bound paclitaxel 10durvalumab 9Erlotinib Hydrochloride 8Trastuzumab 7Bevacizumab 7Taxes 6Platinum 6Magnetic Resonance Spectroscopy 6Biopsy 6Albumin-Bound Paclitaxel 61,2-diaminocyclohexaneplatinum II citrate 6Specimen Handling 5Sorafenib 5Radiotherapy 5Docetaxel 5Carboplatin 5Immunohistochemistry 4trifluridine tipiracil drug combination 3dehydroftorafur 3atezolizumab 3Watchful Waiting 3Tegafur 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gallbladder Neoplasms × Microarray Analysis × Gastrointestinal × Clear all
NCT00486356 2024-01-03

Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer

University of Nebraska

Phase 1 Completed
46 enrolled
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡